APS — Aptose Biosciences Share News
0.000.00%
Last trade - 00:00- CA$6.12m
- CA$51.28m
Brief: Aptose Biosciences Reports Qtrly Net Loss Per Share Of $0.13
Brief: Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And Doses Third Cohort In Phase 1 Study Of APTO-253
Brief: Aptose Says CG-806 Safely And Durably Suppressed Tumor Growth In Preclinical Models
U.S. STOCKS ON THE MOVE-Tilly's, Canadian Solar, Verizon
U.S. STOCKS ON THE MOVE-CBS, PVH, Zynga, Dollar General
Aptose Biosciences: Hits one-month low after discounted share offering
Brief: Aptose Announces Pricing Of Public Offering Of Common Shares
Brief: Aptose Announces Proposed Public Offering Of Common Shares
Brief: Aptose Biosciences Says Equity Distribution Agreement To Issue & Sell Up To Common Shares Having Price Of Up To $40 Mln Through 'At-The-Market'
Brief: Aptose Q1 Loss Per Share C$0.14
Brief: Aptose Biosciences Files For Mixed Shelf Offering For Up To $100 Mln
Brief: Aptose Announces FDA Allowance Of Investigational New Drug Application For CG-806
Brief: Aptose Biosciences Posts Q4 Loss Per Share of C$0.17
Brief: Aptose Biosciences, Crystalgenomics Announce Issuance Of Australian Patent
Brief: Aptose Biosciences Submits IND Application For CG-806
Aptose Biosciences: Rises as Oppenheimer starts with outperform rating
Brief: Aptose Qtrly Loss Per Share $0.16
Brief: Aptose Biosciences And Crystalgenomics Announce Issuance Of European Patent For CG-806
Brief: Aptose Announces Appointment Of Carol Ashe To Board Of Directors